nodes	percent_of_prediction	percent_of_DWPC	metapath
Methazolamide—CYP2E1—Mitoxantrone—lymphatic system cancer	0.132	0.222	CbGbCtD
Methazolamide—CYP2C19—Teniposide—lymphatic system cancer	0.118	0.199	CbGbCtD
Methazolamide—CYP2C9—Teniposide—lymphatic system cancer	0.098	0.166	CbGbCtD
Methazolamide—SLC22A6—Methotrexate—lymphatic system cancer	0.0622	0.105	CbGbCtD
Methazolamide—CYP3A4—Cytarabine—lymphatic system cancer	0.0578	0.0977	CbGbCtD
Methazolamide—CYP3A4—Teniposide—lymphatic system cancer	0.057	0.0963	CbGbCtD
Methazolamide—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0398	0.0673	CbGbCtD
Methazolamide—CYP3A4—Vincristine—lymphatic system cancer	0.0274	0.0463	CbGbCtD
Methazolamide—Crystalluria—Fludarabine—lymphatic system cancer	0.0228	0.0558	CcSEcCtD
Methazolamide—Metabolic acidosis—Teniposide—lymphatic system cancer	0.0171	0.0419	CcSEcCtD
Methazolamide—Metabolic acidosis—Fludarabine—lymphatic system cancer	0.015	0.0369	CcSEcCtD
Methazolamide—Hepatic insufficiency—Methotrexate—lymphatic system cancer	0.0114	0.0279	CcSEcCtD
Methazolamide—Bone marrow depression—Teniposide—lymphatic system cancer	0.01	0.0246	CcSEcCtD
Methazolamide—Digestion impaired—Fludarabine—lymphatic system cancer	0.0089	0.0218	CcSEcCtD
Methazolamide—Bone marrow depression—Fludarabine—lymphatic system cancer	0.00881	0.0216	CcSEcCtD
Methazolamide—Haemolytic anaemia—Mechlorethamine—lymphatic system cancer	0.00738	0.0181	CcSEcCtD
Methazolamide—Pancytopenia—Mechlorethamine—lymphatic system cancer	0.00547	0.0134	CcSEcCtD
Methazolamide—Haemolytic anaemia—Teniposide—lymphatic system cancer	0.00544	0.0133	CcSEcCtD
Methazolamide—Bone marrow depression—Vincristine—lymphatic system cancer	0.00538	0.0132	CcSEcCtD
Methazolamide—Bone marrow depression—Mitoxantrone—lymphatic system cancer	0.00524	0.0128	CcSEcCtD
Methazolamide—Hepatic failure—Fludarabine—lymphatic system cancer	0.0048	0.0118	CcSEcCtD
Methazolamide—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.00479	0.0117	CcSEcCtD
Methazolamide—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.00436	0.0107	CcSEcCtD
Methazolamide—Tinnitus—Mechlorethamine—lymphatic system cancer	0.0043	0.0105	CcSEcCtD
Methazolamide—Pancytopenia—Teniposide—lymphatic system cancer	0.00403	0.00988	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Fludarabine—lymphatic system cancer	0.00389	0.00952	CcSEcCtD
Methazolamide—Vertigo—Mechlorethamine—lymphatic system cancer	0.0036	0.00883	CcSEcCtD
Methazolamide—Leukopenia—Mechlorethamine—lymphatic system cancer	0.00359	0.0088	CcSEcCtD
Methazolamide—Pancytopenia—Fludarabine—lymphatic system cancer	0.00354	0.00868	CcSEcCtD
Methazolamide—Appetite absent—Methotrexate—lymphatic system cancer	0.00354	0.00868	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Fludarabine—lymphatic system cancer	0.0033	0.00808	CcSEcCtD
Methazolamide—Urine output increased—Vincristine—lymphatic system cancer	0.00328	0.00805	CcSEcCtD
Methazolamide—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00327	0.00802	CcSEcCtD
Methazolamide—Haematuria—Fludarabine—lymphatic system cancer	0.00317	0.00777	CcSEcCtD
Methazolamide—Anorexia—Mechlorethamine—lymphatic system cancer	0.00312	0.00765	CcSEcCtD
Methazolamide—Polyuria—Vincristine—lymphatic system cancer	0.003	0.00736	CcSEcCtD
Methazolamide—Hepatic failure—Vincristine—lymphatic system cancer	0.00293	0.00719	CcSEcCtD
Methazolamide—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00285	0.00697	CcSEcCtD
Methazolamide—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00282	0.00692	CcSEcCtD
Methazolamide—Leukopenia—Teniposide—lymphatic system cancer	0.00265	0.00649	CcSEcCtD
Methazolamide—Bone marrow depression—Methotrexate—lymphatic system cancer	0.00261	0.0064	CcSEcCtD
Methazolamide—Pancytopenia—Bleomycin—lymphatic system cancer	0.0026	0.00636	CcSEcCtD
Methazolamide—Confusional state—Teniposide—lymphatic system cancer	0.00243	0.00596	CcSEcCtD
Methazolamide—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00241	0.00591	CcSEcCtD
Methazolamide—Malaise—Fludarabine—lymphatic system cancer	0.00234	0.00574	CcSEcCtD
Methazolamide—Leukopenia—Fludarabine—lymphatic system cancer	0.00233	0.0057	CcSEcCtD
Methazolamide—Haematuria—Bleomycin—lymphatic system cancer	0.00233	0.0057	CcSEcCtD
Methazolamide—Anorexia—Teniposide—lymphatic system cancer	0.0023	0.00564	CcSEcCtD
Methazolamide—Pancytopenia—Carmustine—lymphatic system cancer	0.00227	0.00555	CcSEcCtD
Methazolamide—Convulsion—Fludarabine—lymphatic system cancer	0.00225	0.00552	CcSEcCtD
Methazolamide—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00224	0.00549	CcSEcCtD
Methazolamide—Discomfort—Fludarabine—lymphatic system cancer	0.00219	0.00536	CcSEcCtD
Methazolamide—Pancytopenia—Vincristine—lymphatic system cancer	0.00216	0.0053	CcSEcCtD
Methazolamide—Confusional state—Fludarabine—lymphatic system cancer	0.00214	0.00524	CcSEcCtD
Methazolamide—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00212	0.0052	CcSEcCtD
Methazolamide—Pancytopenia—Mitoxantrone—lymphatic system cancer	0.00211	0.00516	CcSEcCtD
Methazolamide—Decreased appetite—Teniposide—lymphatic system cancer	0.0021	0.00514	CcSEcCtD
Methazolamide—Vomiting—Mechlorethamine—lymphatic system cancer	0.00208	0.0051	CcSEcCtD
Methazolamide—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.00208	0.0051	CcSEcCtD
Methazolamide—Rash—Mechlorethamine—lymphatic system cancer	0.00206	0.00506	CcSEcCtD
Methazolamide—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00206	0.00505	CcSEcCtD
Methazolamide—Anorexia—Fludarabine—lymphatic system cancer	0.00202	0.00495	CcSEcCtD
Methazolamide—Feeling abnormal—Teniposide—lymphatic system cancer	0.00199	0.00487	CcSEcCtD
Methazolamide—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00198	0.00485	CcSEcCtD
Methazolamide—Nausea—Mechlorethamine—lymphatic system cancer	0.00195	0.00476	CcSEcCtD
Methazolamide—Urticaria—Teniposide—lymphatic system cancer	0.00192	0.0047	CcSEcCtD
Methazolamide—Body temperature increased—Teniposide—lymphatic system cancer	0.00191	0.00467	CcSEcCtD
Methazolamide—Paraesthesia—Fludarabine—lymphatic system cancer	0.00191	0.00467	CcSEcCtD
Methazolamide—Haematuria—Mitoxantrone—lymphatic system cancer	0.00189	0.00462	CcSEcCtD
Methazolamide—Dyspepsia—Fludarabine—lymphatic system cancer	0.00187	0.00457	CcSEcCtD
Methazolamide—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00185	0.00452	CcSEcCtD
Methazolamide—Decreased appetite—Fludarabine—lymphatic system cancer	0.00184	0.00452	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00183	0.00449	CcSEcCtD
Methazolamide—Fatigue—Fludarabine—lymphatic system cancer	0.00183	0.00448	CcSEcCtD
Methazolamide—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00177	0.00433	CcSEcCtD
Methazolamide—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00175	0.00428	CcSEcCtD
Methazolamide—Asthenia—Teniposide—lymphatic system cancer	0.00173	0.00424	CcSEcCtD
Methazolamide—Melaena—Methotrexate—lymphatic system cancer	0.00172	0.00422	CcSEcCtD
Methazolamide—Malaise—Bleomycin—lymphatic system cancer	0.00172	0.00421	CcSEcCtD
Methazolamide—Leukopenia—Bleomycin—lymphatic system cancer	0.00171	0.00418	CcSEcCtD
Methazolamide—Body temperature increased—Fludarabine—lymphatic system cancer	0.00168	0.00411	CcSEcCtD
Methazolamide—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.00166	0.00405	CcSEcCtD
Methazolamide—Diarrhoea—Teniposide—lymphatic system cancer	0.00165	0.00405	CcSEcCtD
Methazolamide—Discomfort—Bleomycin—lymphatic system cancer	0.0016	0.00393	CcSEcCtD
Methazolamide—Urine output increased—Methotrexate—lymphatic system cancer	0.00159	0.0039	CcSEcCtD
Methazolamide—Confusional state—Bleomycin—lymphatic system cancer	0.00157	0.00384	CcSEcCtD
Methazolamide—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00156	0.00381	CcSEcCtD
Methazolamide—Vomiting—Teniposide—lymphatic system cancer	0.00153	0.00376	CcSEcCtD
Methazolamide—Asthenia—Fludarabine—lymphatic system cancer	0.00152	0.00373	CcSEcCtD
Methazolamide—Rash—Teniposide—lymphatic system cancer	0.00152	0.00373	CcSEcCtD
Methazolamide—Dermatitis—Teniposide—lymphatic system cancer	0.00152	0.00372	CcSEcCtD
Methazolamide—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00151	0.00371	CcSEcCtD
Methazolamide—Headache—Teniposide—lymphatic system cancer	0.00151	0.0037	CcSEcCtD
Methazolamide—Leukopenia—Carmustine—lymphatic system cancer	0.00149	0.00365	CcSEcCtD
Methazolamide—Anorexia—Bleomycin—lymphatic system cancer	0.00148	0.00363	CcSEcCtD
Methazolamide—Photosensitivity—Methotrexate—lymphatic system cancer	0.00146	0.00357	CcSEcCtD
Methazolamide—Polyuria—Methotrexate—lymphatic system cancer	0.00146	0.00357	CcSEcCtD
Methazolamide—Diarrhoea—Fludarabine—lymphatic system cancer	0.00145	0.00356	CcSEcCtD
Methazolamide—Convulsion—Carmustine—lymphatic system cancer	0.00144	0.00353	CcSEcCtD
Methazolamide—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00144	0.00352	CcSEcCtD
Methazolamide—Nausea—Teniposide—lymphatic system cancer	0.00143	0.00351	CcSEcCtD
Methazolamide—Vertigo—Vincristine—lymphatic system cancer	0.00143	0.0035	CcSEcCtD
Methazolamide—Hepatic failure—Methotrexate—lymphatic system cancer	0.00142	0.00349	CcSEcCtD
Methazolamide—Leukopenia—Vincristine—lymphatic system cancer	0.00142	0.00348	CcSEcCtD
Methazolamide—Paraesthesia—Bleomycin—lymphatic system cancer	0.0014	0.00342	CcSEcCtD
Methazolamide—Malaise—Mitoxantrone—lymphatic system cancer	0.00139	0.00342	CcSEcCtD
Methazolamide—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00138	0.00339	CcSEcCtD
Methazolamide—Convulsion—Vincristine—lymphatic system cancer	0.00138	0.00337	CcSEcCtD
Methazolamide—Confusional state—Carmustine—lymphatic system cancer	0.00137	0.00335	CcSEcCtD
Methazolamide—Decreased appetite—Bleomycin—lymphatic system cancer	0.00135	0.00331	CcSEcCtD
Methazolamide—Vomiting—Fludarabine—lymphatic system cancer	0.00135	0.0033	CcSEcCtD
Methazolamide—Convulsion—Mitoxantrone—lymphatic system cancer	0.00134	0.00328	CcSEcCtD
Methazolamide—Rash—Fludarabine—lymphatic system cancer	0.00134	0.00328	CcSEcCtD
Methazolamide—Dermatitis—Fludarabine—lymphatic system cancer	0.00134	0.00327	CcSEcCtD
Methazolamide—Headache—Fludarabine—lymphatic system cancer	0.00133	0.00326	CcSEcCtD
Methazolamide—Discomfort—Mitoxantrone—lymphatic system cancer	0.0013	0.00319	CcSEcCtD
Methazolamide—Anaphylactic shock—Vincristine—lymphatic system cancer	0.0013	0.00318	CcSEcCtD
Methazolamide—Anorexia—Carmustine—lymphatic system cancer	0.00129	0.00317	CcSEcCtD
Methazolamide—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00128	0.00314	CcSEcCtD
Methazolamide—Confusional state—Mitoxantrone—lymphatic system cancer	0.00127	0.00312	CcSEcCtD
Methazolamide—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00126	0.00309	CcSEcCtD
Methazolamide—Nausea—Fludarabine—lymphatic system cancer	0.00126	0.00309	CcSEcCtD
Methazolamide—Urticaria—Bleomycin—lymphatic system cancer	0.00124	0.00303	CcSEcCtD
Methazolamide—Anorexia—Vincristine—lymphatic system cancer	0.00124	0.00303	CcSEcCtD
Methazolamide—Body temperature increased—Bleomycin—lymphatic system cancer	0.00123	0.00301	CcSEcCtD
Methazolamide—Paraesthesia—Carmustine—lymphatic system cancer	0.00122	0.00299	CcSEcCtD
Methazolamide—Somnolence—Carmustine—lymphatic system cancer	0.00121	0.00296	CcSEcCtD
Methazolamide—Anorexia—Mitoxantrone—lymphatic system cancer	0.0012	0.00295	CcSEcCtD
Methazolamide—Decreased appetite—Carmustine—lymphatic system cancer	0.00118	0.00289	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00117	0.00287	CcSEcCtD
Methazolamide—Paraesthesia—Vincristine—lymphatic system cancer	0.00116	0.00285	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00115	0.00282	CcSEcCtD
Methazolamide—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00113	0.00278	CcSEcCtD
Methazolamide—Decreased appetite—Vincristine—lymphatic system cancer	0.00113	0.00276	CcSEcCtD
Methazolamide—Somnolence—Mitoxantrone—lymphatic system cancer	0.00112	0.00275	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00112	0.00274	CcSEcCtD
Methazolamide—Feeling abnormal—Carmustine—lymphatic system cancer	0.00112	0.00274	CcSEcCtD
Methazolamide—Fatigue—Vincristine—lymphatic system cancer	0.00112	0.00274	CcSEcCtD
Methazolamide—Asthenia—Bleomycin—lymphatic system cancer	0.00112	0.00273	CcSEcCtD
Methazolamide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00111	0.00272	CcSEcCtD
Methazolamide—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.0011	0.00269	CcSEcCtD
Methazolamide—Fatigue—Mitoxantrone—lymphatic system cancer	0.00109	0.00267	CcSEcCtD
Methazolamide—Body temperature increased—Carmustine—lymphatic system cancer	0.00107	0.00263	CcSEcCtD
Methazolamide—Pancytopenia—Methotrexate—lymphatic system cancer	0.00105	0.00257	CcSEcCtD
Methazolamide—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00104	0.00255	CcSEcCtD
Methazolamide—Body temperature increased—Vincristine—lymphatic system cancer	0.00102	0.00251	CcSEcCtD
Methazolamide—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00101	0.00247	CcSEcCtD
Methazolamide—Urticaria—Mitoxantrone—lymphatic system cancer	0.001	0.00246	CcSEcCtD
Methazolamide—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000998	0.00244	CcSEcCtD
Methazolamide—Vomiting—Bleomycin—lymphatic system cancer	0.000989	0.00242	CcSEcCtD
Methazolamide—Drowsiness—Methotrexate—lymphatic system cancer	0.000986	0.00242	CcSEcCtD
Methazolamide—Rash—Bleomycin—lymphatic system cancer	0.000981	0.0024	CcSEcCtD
Methazolamide—Dermatitis—Bleomycin—lymphatic system cancer	0.00098	0.0024	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000978	0.00239	CcSEcCtD
Methazolamide—Asthenia—Carmustine—lymphatic system cancer	0.000974	0.00239	CcSEcCtD
Methazolamide—Haematuria—Methotrexate—lymphatic system cancer	0.00094	0.0023	CcSEcCtD
Methazolamide—Asthenia—Vincristine—lymphatic system cancer	0.00093	0.00228	CcSEcCtD
Methazolamide—Diarrhoea—Carmustine—lymphatic system cancer	0.000929	0.00228	CcSEcCtD
Methazolamide—Nausea—Bleomycin—lymphatic system cancer	0.000924	0.00226	CcSEcCtD
Methazolamide—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00092	0.00225	CcSEcCtD
Methazolamide—Asthenia—Mitoxantrone—lymphatic system cancer	0.000906	0.00222	CcSEcCtD
Methazolamide—Diarrhoea—Vincristine—lymphatic system cancer	0.000887	0.00217	CcSEcCtD
Methazolamide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000864	0.00212	CcSEcCtD
Methazolamide—Vomiting—Carmustine—lymphatic system cancer	0.000863	0.00211	CcSEcCtD
Methazolamide—Rash—Carmustine—lymphatic system cancer	0.000856	0.0021	CcSEcCtD
Methazolamide—Dermatitis—Carmustine—lymphatic system cancer	0.000855	0.0021	CcSEcCtD
Methazolamide—Headache—Carmustine—lymphatic system cancer	0.000851	0.00208	CcSEcCtD
Methazolamide—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000837	0.00205	CcSEcCtD
Methazolamide—Tinnitus—Methotrexate—lymphatic system cancer	0.000825	0.00202	CcSEcCtD
Methazolamide—Vomiting—Vincristine—lymphatic system cancer	0.000824	0.00202	CcSEcCtD
Methazolamide—Rash—Vincristine—lymphatic system cancer	0.000817	0.002	CcSEcCtD
Methazolamide—Dermatitis—Vincristine—lymphatic system cancer	0.000817	0.002	CcSEcCtD
Methazolamide—Headache—Vincristine—lymphatic system cancer	0.000812	0.00199	CcSEcCtD
Methazolamide—Nausea—Carmustine—lymphatic system cancer	0.000807	0.00198	CcSEcCtD
Methazolamide—Vomiting—Mitoxantrone—lymphatic system cancer	0.000803	0.00197	CcSEcCtD
Methazolamide—Rash—Mitoxantrone—lymphatic system cancer	0.000796	0.00195	CcSEcCtD
Methazolamide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000795	0.00195	CcSEcCtD
Methazolamide—Headache—Mitoxantrone—lymphatic system cancer	0.000791	0.00194	CcSEcCtD
Methazolamide—Nausea—Vincristine—lymphatic system cancer	0.00077	0.00189	CcSEcCtD
Methazolamide—Dysgeusia—Methotrexate—lymphatic system cancer	0.000755	0.00185	CcSEcCtD
Methazolamide—Nausea—Mitoxantrone—lymphatic system cancer	0.00075	0.00184	CcSEcCtD
Methazolamide—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000715	0.00175	CcSEcCtD
Methazolamide—Malaise—Methotrexate—lymphatic system cancer	0.000695	0.0017	CcSEcCtD
Methazolamide—Vertigo—Methotrexate—lymphatic system cancer	0.000692	0.0017	CcSEcCtD
Methazolamide—Leukopenia—Methotrexate—lymphatic system cancer	0.00069	0.00169	CcSEcCtD
Methazolamide—Convulsion—Methotrexate—lymphatic system cancer	0.000668	0.00164	CcSEcCtD
Methazolamide—Discomfort—Methotrexate—lymphatic system cancer	0.000648	0.00159	CcSEcCtD
Methazolamide—Confusional state—Methotrexate—lymphatic system cancer	0.000634	0.00155	CcSEcCtD
Methazolamide—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000629	0.00154	CcSEcCtD
Methazolamide—Anorexia—Methotrexate—lymphatic system cancer	0.0006	0.00147	CcSEcCtD
Methazolamide—Paraesthesia—Methotrexate—lymphatic system cancer	0.000565	0.00138	CcSEcCtD
Methazolamide—Somnolence—Methotrexate—lymphatic system cancer	0.000559	0.00137	CcSEcCtD
Methazolamide—Dyspepsia—Methotrexate—lymphatic system cancer	0.000554	0.00136	CcSEcCtD
Methazolamide—Decreased appetite—Methotrexate—lymphatic system cancer	0.000547	0.00134	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000543	0.00133	CcSEcCtD
Methazolamide—Fatigue—Methotrexate—lymphatic system cancer	0.000542	0.00133	CcSEcCtD
Methazolamide—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000518	0.00127	CcSEcCtD
Methazolamide—Urticaria—Methotrexate—lymphatic system cancer	0.0005	0.00122	CcSEcCtD
Methazolamide—Body temperature increased—Methotrexate—lymphatic system cancer	0.000497	0.00122	CcSEcCtD
Methazolamide—Asthenia—Methotrexate—lymphatic system cancer	0.000451	0.00111	CcSEcCtD
Methazolamide—Diarrhoea—Methotrexate—lymphatic system cancer	0.00043	0.00105	CcSEcCtD
Methazolamide—Vomiting—Methotrexate—lymphatic system cancer	0.0004	0.00098	CcSEcCtD
Methazolamide—Rash—Methotrexate—lymphatic system cancer	0.000397	0.000971	CcSEcCtD
Methazolamide—Dermatitis—Methotrexate—lymphatic system cancer	0.000396	0.00097	CcSEcCtD
Methazolamide—Headache—Methotrexate—lymphatic system cancer	0.000394	0.000965	CcSEcCtD
Methazolamide—Nausea—Methotrexate—lymphatic system cancer	0.000374	0.000915	CcSEcCtD
